{
    "name": "alirocumab",
    "comment": "Rx",
    "other_names": [
        "Praluent"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "PCSK9 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/praluent-alirocumab-999998",
    "pregnancy": {
        "common": [
            "Available data from clinical trials and postmarketing reports in pregnant females are insufficient to evaluate for drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes ",
            "There is a pregnancy safety study if administered during pregnancy; report exposure (1-844-734-6643)"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Studies in rats have not shown effects on embryo-fetal development when given during organogenesis up to 12-fold the human exposure",
                    "In monkeys, suppression of the humoral immune response was observed in infant monkeys when alirocumab was dosed during organogenesis to parturition at dose exposures 13-fold the exposure at the maximum recommended human dose of 150 mg q2wk",
                    "Measurable alirocumab serum concentrations observed in infant monkeys at birth at comparable levels to maternal serum, indicating that it crosses the placental barrier; monoclonal antibodies are transported across placenta in increasing amounts especially near term; therefore, it has the potential to be transmitted from mother to developing fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "The development and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed infant",
            "Human IgG is present in human milk, but published data suggest that breastmilk IgG antibodies do not enter the neonatal and infant circulation in substantial amounts"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious hypersensitivity reaction to alirocumab or its exceipeints; reactions have included hypersensitivity vasculitis, angioedema, and hypersensitivity reactions requiring hospitalization"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (eg, pruritus, rash, urticaria), including some serious events (eg, hypersensitivity vasculitis and hypersensitivity reactions requiring hospitalization), have been reported; discontinue and treat if signs or symptoms of serious allergic reactions occur"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nasopharyngitis",
            "percent": "11.3"
        },
        {
            "name": "Allergic reactions",
            "percent": "8.6"
        },
        {
            "name": "Injection site reactions",
            "percent": "7.2"
        },
        {
            "name": "Influenza",
            "percent": "5.7"
        },
        {
            "name": "Antidrug antibodies",
            "percent": "4.8"
        },
        {
            "name": "Urinary tract infection",
            "percent": "4.8"
        },
        {
            "name": "Diarrhea",
            "percent": "4.7"
        },
        {
            "name": "Bronchitis",
            "percent": "4.3"
        },
        {
            "name": "Myalgia",
            "percent": "4.2"
        },
        {
            "name": "Muscle spasms",
            "percent": "3.1"
        },
        {
            "name": "Sinusitis",
            "percent": "3"
        },
        {
            "name": "Liver",
            "percent": "2.5"
        },
        {
            "name": "related disorders",
            "percent": "2.5"
        },
        {
            "name": "Cough",
            "percent": "2.1"
        },
        {
            "name": "Contusion",
            "percent": "2.1"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Vasculitis",
            "percent": null
        }
    ]
}